- Home
- ESNT vs RLAY Comparison
ESNT vs RLAY Comparison
Compare ESNT & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESNT
- RLAY
- Stock Information
- Founded
- ESNT 2008
- RLAY 2015
- Country
- ESNT Bermuda
- RLAY United States
- Employees
- ESNT 510
- RLAY N/A
- Industry
- ESNT Property-Casualty Insurers
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESNT Finance
- RLAY Health Care
- Exchange
- ESNT Nasdaq
- RLAY Nasdaq
- Market Cap
- ESNT 5.9B
- RLAY 1.0B
- IPO Year
- ESNT 2013
- RLAY 2020
- Fundamental
- Price
- ESNT $61.82
- RLAY $6.40
- Analyst Decision
- ESNT Buy
- RLAY Strong Buy
- Analyst Count
- ESNT 5
- RLAY 9
- Target Price
- ESNT $66.80
- RLAY $16.00
- AVG Volume (30 Days)
- ESNT 557.6K
- RLAY 2.4M
- Earning Date
- ESNT 11-07-2025
- RLAY 11-06-2025
- Dividend Yield
- ESNT 2.02%
- RLAY N/A
- EPS Growth
- ESNT N/A
- RLAY N/A
- EPS
- ESNT 6.87
- RLAY N/A
- Revenue
- ESNT $1,263,558,000.00
- RLAY $8,355,000.00
- Revenue This Year
- ESNT $4.19
- RLAY $27.30
- Revenue Next Year
- ESNT $1.54
- RLAY $7.43
- P/E Ratio
- ESNT $8.94
- RLAY N/A
- Revenue Growth
- ESNT 2.04
- RLAY N/A
- 52 Week Low
- ESNT $51.61
- RLAY $1.78
- 52 Week High
- ESNT $65.90
- RLAY $7.64
- Technical
- Relative Strength Index (RSI)
- ESNT 54.30
- RLAY 50.15
- Support Level
- ESNT $60.08
- RLAY $6.17
- Resistance Level
- ESNT $62.52
- RLAY $6.76
- Average True Range (ATR)
- ESNT 1.41
- RLAY 0.44
- MACD
- ESNT 0.06
- RLAY -0.09
- Stochastic Oscillator
- ESNT 86.07
- RLAY 34.23
About ESNT Essent Group Ltd.
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).